Transforming Immunotherapy

Our lead therapeutic candidate IC14 is an investigational anti-CD14 monoclonal antibody

IC14 regulates pathogenic inflammatory responses to infection and injury, and has great potential across a variety of disease areas. Right now, we are focused on testing its efficacy in the fight against motor neurone disease (MND) or amyotrophic lateral sclerosis (ALS); cardioimmunology; and all-cause acute respiratory distress syndrome (ARDS) .


We have united world-leaders in medical research, clinical practice and commercialisation.

Meet the team


IC14 is a novel monoclonal antibody designed to block CD14 – a master regulator of the body’s immune response.

Learn More


We are a private company, with a noble investment proposition, welcoming support from philanthropists, private investors and government sources.

Partner with us

“The chronic diseases that afflict us as we age are largely the result of inappropriate inflammation, so the ability of IC14 to reset the level of inflammation should be game-changing for these diseases.“

– Scientific Advisor, Prof Ian Frazer

Current Clinical Trials


IC14 has been selected for inclusion in a platform Phase 2 clinical study by the Healey Center at Massachusetts General Hospital.


IC14 has been selected for inclusion in two funded multicentre Phase 2 clinical studies in the US, to reduce the severity of respiratory disease in people hospitalised due to COVID-19.

Brave and brilliant minds

We are a multidisciplinary team of thinkers, doers and makers.